BioPharmaceutical Business Intelligence

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Express Scripts
QuintilesIMS
Julphar
Cerilliant
Chinese Patent Office
Farmers Insurance
Harvard Business School
Cantor Fitzgerald
AstraZeneca

Generated: January 16, 2018

DrugPatentWatch Database Preview

Claims for Patent: 5,914,332

« Back to Dashboard

Summary for Patent: 5,914,332
Title: Retroviral protease inhibiting compounds
Abstract:A compound of the formula: ##STR1## is disclosed as an HIV protease inhibitor. Methods and compositions for inhibiting an HIV infection are also disclosed.
Inventor(s): Sham; Hing Leung (Mundelein, IL), Norbeck; Daniel W. (Crystal Lake, IL), Chen; Xiaoqi (Libertyville, IL), Betebenner; David A. (Gurnee, IL)
Assignee: Abbott Laboratories (Abbott Park, IL)
Application Number:08/753,201
Patent Claims: 1. A compound of the formula: ##STR84## wherein R.sub.1 and R.sub.2 are independently selected from the group consisting of loweralkyl, cycloalkylalkyl and arylalkyl;

R.sub.3 is loweralkyl, hydroxyalkyl or cycloalkylalkyl;

R.sub.4 is aryl;

R.sub.5 is ##STR85## wherein n is 1, 2 or 3, X is O, S or NH and Y is --O-- or --N(R.sub.6)-- wherein R.sub.6 is hydrogen, loweralkyl, cycloalkyl, cycloalkylalkyl, aryl or arylalkyl;

and

L.sub.1 is

a) --O--,

b) --S--,

c) --N(R.sub.7)-- wherein R.sub.7 is hydrogen, loweralkyl, cycloalkyl or cycloalkylalkyl,

d) --O-alkylenyl-,

e) --S-alkylenyl-

f) --S(O)-alkylenyl-,

g) --S(O).sub.2 -alkylenyl-,

h) --N(R.sub.7)-alkylenyl- wherein R.sub.7 is defined as above,

i) -alkylenyl-O--,

j) -alkylenyl-S--,

k) alkylenyl-N(R.sub.7)-- wherein R.sub.7 is defined as above,

l) alkylenyl or

m) alkenylenyl;

or a pharmaceutically acceptable salt, ester or prodrug thereof.

2. A compound according to claim 1 wherein R.sub.1 and R.sub.2 are arylalkyl, R.sub.3 is loweralkyl, R.sub.4 is aryl, R.sub.5 is ##STR86## wherein X, Y and n are defined as therein and L.sub.1 is --O-alkylenyl.

3. A compound according to claim 1 wherein R.sub.1 and R.sub.2 are benzyl or R.sub.1 is benzyl and R.sub.2 is loweralkyl, R.sub.3 is loweralkyl, R.sub.4 is phenyl which is substituted with two loweralkyl groups and which is optionally substituted with a third substituent selected from the group consisting of loweralkyl, hydroxy, amino and halo, R.sub.5 is ##STR87## wherein n is 1 or 2, X is O or S and Y is --NH--, and

L.sub.1 is --O--CH.sub.2 --.

4. A compound according to claim 1 wherein R.sub.1 and R.sub.2 are benzyl or R.sub.1 is benzyl and R.sub.2 is isopropyl, R.sub.3 is loweralkyl, R.sub.4 is 2,6-dimethylphenyl which is optionally substituted with a third substituent selected from the group consisting of loweralkyl and halo, R.sub.5 is ##STR88## wherein n is 1 or 2, X is O or S and Y is --NH--, and

L.sub.1 is --O--CH.sub.2 --.

5. A compound according to claim 1 wherein R.sub.1 and R.sub.2 are benzyl or R.sub.1 is benzyl and R.sub.2 is isopropyl, R.sub.3 is loweralkyl, R.sub.4 is 2,6-dimethylphenyl which is optionally substituted with a third substituent selected from the group consisting of loweralkyl and halo, R.sub.5 is ##STR89## wherein n is 1 or 2, X is O or S and Y is --NH-- and L.sub.1 is --O--CH.sub.2 --.

6. A compound selected from the group consisting of:

(2S,3S,5S)-2-(2,6-dimethylphenoxyacetyl)amino-3-hydroxy-5-[2S-(1-tetrahydro -pyrimid-2-onyl)-3-methyl butanoyl]amino-1,6-diphenylhexane;

(2S,3S,5S)-2-(2,6-Dimethylphenoxyacetyl)amino-3-hydroxy-5-(2S-(1-imidazolid in-2-onyl)-3,3dimethyl butanoyl)amino-1,6-diphenylhexane;

(2S,3S,5S)-2-(2,6-dimethylphenoxyacetyl)amino-3-hydroxy-5-(2S-(1-imidazolid in-2-thionyl)-3-methyl butanoyl)amino-1,6-diphenylhexane;

(2S,3S,5S)-2-(2,4,6-trimethylphenoxyacetyl)amino-3-hydroxy-5-(2S-(1-imidazo lidin-2-onyl-3-methylbutanoyl)amino-1,6-diphenylhexane;

(2S,3S,5S)-2-(4-fluoro-2,6-dimethylphenoxyacetyl)amino-3-hydroxy-5-(2S-(1-i mmidazolidin-2-onyl)-3-methylbutanoyl)amino-1,6-diphenylhexane;

(2S,3S,5S)-2-(trans-3-(2,6-dimethylphenyl)propenoyl)amino-3-hydroxy-5-(2S-1 -tetrahydropyrimidin-2-onyl)-3-methyl-butanoyl)amino-1,6-diphenylhexane;

(2S,3S,5S)-2-(3-(2,6-dimethylphenyl)propanoyl)amino-3-hydroxy-5-(2S-(1-tetr ahydropyrimidin-2-onyl)-3-methyl-butanoyl)amino-1,6-diphenylhexane;

(2S,3S,5S)-2-(2,6-Dimethylphenoxyacetyl)amino-3-hydroxy-5-(2S-(1-tetrahydro -pyrimid-2-onyl)-3-methylbutanoyl)amino-1-phenyl-6-methylheptane;

or a pharmaceutically acceptable salt, ester or prodrug thereof.

7. The compound (2S,3S,5S)-2-(2,6-dimethylphenoxyacetyl)amino-3-hydroxy-5-(2S-(1-tetrahydr o-pyrimid-2-onyl)-3-methyl butanoyl)amino-1,6-diphenylhexane;

or a pharmaceutically acceptable salt, ester or pyodrug thereof.

8. The compound (2S,3S,5S)-2-(2,6-dimethylphenoxyacetyl)amino-3-hydroxy-5-(2-(1-tetrahydro -pyrimid-2-onyl)-3-methyl butanoyl)amino-1,6-diphenylhexane;

or a pharmaceutically acceptable salt thereof.

9. A pharmaceutical composition for inhibiting HIV protease comprising a pharmaceutical carrier and a therapeutically effective amount of the compound of claim 1.

10. A pharmaceutical composition for inhibiting HIV protease comprising a pharmaceutical carrier and a therapeutically effective amount of the compound of claim 7.

11. A pharmaceutical composition for inhibiting HIV protease comprising a pharmaceutical carrier and a therapeutically effective amount of the compound of claim 8.

12. A method for inhibiting HIV protease comprising administering to a human in need of such treatment a therapeuctially effective amount of the compound of claim 1.

13. A method for inhibiting HIV protease comprising administering to a human in need of such treatment a therapeuctially effective amount of the compound of claim 7.

14. A method for inhibiting an HIV infection comprising administering to a human in need of such treatment a therapeuctially effective amount of the compound of claim 1.

15. A method for inhibiting an HIV infection comprising administering to a human in need of such treatment a therapeuctially effective amount of the compound of claim 7.

16. A method for inhibiting HIV protease comprising administering to a human in need of such treatment a therapeuctially effective amount of the compound of claim 8.

17. A method for inhibiting an HIV infection comprising administering to a human in need of such treatment a therapeuctially effective amount of the compound of claim 8.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Cantor Fitzgerald
Cerilliant
Accenture
Citi
AstraZeneca
Queensland Health
UBS
Federal Trade Commission
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot